Basil Systems Raises $11.5 Million to Enhance AI-Powered Lifecycle Management
Basil Systems has secured $11.5 million in funding led by Golden Ventures, with participation from Hearst Ventures and Argosy Capital. The capital will support the expansion of Basil's enterprise SaaS platform, BasilIntel, improve product features, and speed up the delivery of data-driven insights in the pharmaceutical and medical device sectors.
The funding enables Basil to increase its data coverage, bring on new enterprise clients, and extend the deployment of AI and machine learning to automate complex, high-stakes workflows. The company also plans to broaden its support to include drug and device manufacturers, suppliers, clinical research organizations, and regulatory agencies across the life sciences ecosystem.
Transforming Regulatory Intelligence with AI
Life sciences companies often grapple with manual processes, siloed data, and outdated tools for vital operations such as regulatory submissions, clinical planning, and post-market surveillance. Basil Systems addresses these challenges by delivering real-time, AI-driven intelligence that accelerates decision-making, enhances collaboration, and reduces risk.
BasilIntel provides answers to complex questions quickly, such as identifying materials linked to implant failures or comparing label changes across therapies. This is possible thanks to BasilLink, the largest indexed dataset in life sciences, containing over 600 million continuously updated records including regulatory submissions, drug labels, clinical trials, adverse event reports, and more.
Comprehensive Data and Scalable AI Platform
The platform uses a natural language interface and API connectivity, supported by enterprise-grade infrastructure capable of handling millions of concurrent users. It unifies scattered data into a single, fully indexed source, enabling faster insights and leaner operations.
Anthony Cirurgiao, Founder and CEO of Basil Systems, highlights that the platform transforms massive datasets into real-time answers that support strategic decisions across innovation, regulatory compliance, safety, and commercialization.
Trusted by Industry Leaders
BasilIntel is already in use by four of the five largest global medical device companies and is undergoing trials with three top pharmaceutical firms. This adoption underscores the platform’s ability to replace fragmented, unreliable systems with a streamlined, data-driven solution.
Mohamed Shariff, Director of Regulatory Affairs at Johnson & Johnson, notes that Basil provides unmatched depth in regulatory and real-world data, offering visibility and analytics essential for faster, smarter decision-making. The platform is becoming a core infrastructure for data-driven strategies in life sciences.
Supporting Multiple Life Sciences Functions
- Strategic product development
- Supply chain optimization
- Risk mitigation
- Real-world evidence (RWE) analysis
- Regulatory, clinical, quality, medical affairs, and commercial divisions
Basil Systems delivers a unified system of record and intelligence, transforming how pharmaceutical and medtech companies manage regulatory, clinical, and product lifecycle strategies. By structuring the largest indexed database of regulatory, drug, device, and post-market data, Basil helps organizations accelerate development, reduce risk, and improve product performance.
For management professionals looking to leverage AI in life sciences, understanding platforms like BasilIntel is essential. To explore AI tools and training that can support this transition, consider visiting Complete AI Training.
Your membership also unlocks:
